Article
Infectious Diseases
Xiuting Hu, Wei Cheng, Shengxian Fan, Yuhua Huang, Xi Chen, Zhiwei Jiang, Jian Wang
Summary: The study confirmed bacterial and fungal dysbiosis in type 2 SBS rats, and GLP-2 partially ameliorated these microbiota dysbiosis.
BMC INFECTIOUS DISEASES
(2021)
Review
Gastroenterology & Hepatology
Marco Pizzoferrato, Pierluigi Puca, Sara Ennas, Giovanni Cammarota, Luisa Guidi
Summary: Short bowel syndrome is a severe complication of Crohn's disease, and drug treatment can reduce patients' dependence on parenteral support.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Biochemical Research Methods
Aleksandra E. Badaczewska-Dawid, Sebastian Kmiecik, Michal Kolinski
Summary: The three-stage molecular docking protocol for GPCR-peptide ligands produces high resolution models for the top-scored complexes, which can be further refined and improved to sub-angstrom accuracy through high-resolution refinement and minimization.
BRIEFINGS IN BIOINFORMATICS
(2021)
Review
Biochemistry & Molecular Biology
Oanh Vu, Brian Joseph Bender, Lisa Pankewitz, Daniel Huster, Annette G. Beck-Sickinger, Jens Meiler
Summary: G protein-coupled receptors (GPCRs) are the largest membrane protein family and a significant target class for therapeutics. The class A receptors of GPCRs affect various aspects of human physiology. Many peptides that bind to these receptors undergo interaction and conformational changes.
Review
Nutrition & Dietetics
Astrid Verbiest, Palle Bekker Jeppesen, Francisca Joly, Tim Vanuytsel
Summary: Short bowel syndrome (SBS) is a rare gastrointestinal condition caused by extensive surgical resection, resulting in less than 200 cm of remaining small intestine. This condition is associated with a high risk for intestinal failure (IF) and requires parenteral support (PS). This review focuses on the role of the colon in SBS-IF, including intestinal adaptation, energy salvage, and the impact of the microbiota. Additionally, the effects of glucagon-like peptide-2 (GLP-2) analogs, a disease-modifying treatment, in SBS-IF patients with and without a colon are discussed. Overall, this review emphasizes the importance of preserving the colon in SBS-IF.
Article
Endocrinology & Metabolism
Leila Arbabi, Qun Li, Belinda A. Henry, Iain J. Clarke
Summary: The study showed that GLP-1 may stimulate GnRH secretion at the level of the secretory terminals of GnRH neurons in the median eminence. It was found that the GLP-1 receptor is mainly expressed in Kisspeptin cells, with minimal expression in GnRH and NPY cells.
JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Nutrition & Dietetics
Daniela Gattini, Christina Belza, Raphael Kraus, Yaron Avitzur, Wendy J. Ungar, Paul W. Wales
Summary: This study compared the cost-effectiveness of teduglutide with standard care in children with short bowel syndrome (SBS). The results showed that although teduglutide was not cost-effective initially, starting the treatment after natural intestinal adaptation and adjusting the cost based on weight dosing made it a cost-effective intervention compared to standard care.
CLINICAL NUTRITION
(2023)
Review
Immunology
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, Durga Lohana, Parkash Kumar, Savitri Aninditha Nandula, Fatima Kausar Nawaz, Kevin Tracey, Huan Yang, Derek LeRoith, Michael J. Brownstein, Jesse Roth
Summary: Inflammation is involved in many chronic conditions and stimulates the release of pro-inflammatory cytokines and immune cells. GLP-1 levels are associated with disease severity and can serve as markers of inflammation. Previous studies have investigated the anti-inflammatory properties of oxytocin, hCG, ghrelin, alpha-MSH and ACTH, while the anti-inflammatory effects of GLP-1 have only recently been recognized. GLP-1 has been shown to be beneficial in treating type-2 diabetes, metabolic syndrome, and hyperglycemia by reducing inflammation and cell death.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Endocrinology & Metabolism
Mark M. Smits, Jens J. Holst
Summary: In recent years, the beneficial effects of GLP-1 receptor agonists have been observed, such as reducing cardiovascular risk in patients with type 2 diabetes and body weight in those with obesity. However, there are differences in their routes of action compared to endogenous GLP-1. It may be useful to develop agents that stimulate GLP-1 release in order to overcome the limitations of GLP-1 receptor agonists.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2023)
Article
Nutrition & Dietetics
Janine Buettner, Elisabeth Bluethner, Sophie Greif, Anja Kuehl, Sefer Elezkurtaj, Jan Ulrich, Sebastian Maasberg, Christoph Jochum, Frank Tacke, Ulrich-Frank Pape
Summary: This study investigated biomarkers for the regulation mechanisms in the intestinal barrier during adaptive response or treatment with the glucagon-like peptide-2 analog in short bowel syndrome patients. Gene expression analyses and intestinal permeability testing were conducted. The results showed altered gene expression in nutrient transport genes and the usefulness of mannitol recovery in describing gut absorptive capacity.
Article
Chemistry, Medicinal
Neng Jiang, Lin Jing, Qing Li, Sibiao Su, Qimeng Yang, Feng Zhou, Xinyu Chen, Jing Han, Chunli Tang, Weizhong Tang
Summary: Dual activation of the glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) can potentially lead to effective therapy for diabetes and obesity. Novel peptides with dual activity on GLP-1R and GCGR were discovered through rational design, with xGLP/GCG-15 showing promising anti-obesity and anti-diabetic effects in preclinical studies.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Gastroenterology & Hepatology
Beatrice E. Rosete, Danielle Wendel, Simon P. Horslen
Summary: Teduglutide, a GLP-2 analog, has been approved for use in pediatric SBS patients over 1 year old as a novel agent that enhances intestinal adaptation. It is the first successful pharmacological intervention to safely and effectively augment the natural process of adaptation in SBS pediatric patients, but more studies and further development are needed to optimize its potential in other pediatric patients.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Review
Medicine, Research & Experimental
Changzhen Zhu, Yuanxin Li
Summary: Short bowel syndrome is a clinical condition that can be treated with intestinal replacement and rehabilitation. Recent research advancements have shown significant progress in using nutritional intestinal hormones for rehabilitation in patients with SBS.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2022)
Article
Nutrition & Dietetics
Fabio Dario Merlo, Umberto Aimasso, Marta Ossola, Mirko Ippolito, Leila Cravero, Valentina Ponzo, Simona Bo
Summary: Liraglutide has beneficial effects on fecal output in short bowel syndrome patients after surgical resection. A pilot observational study showed that after 6 months of treatment, the median ostomy/fecal output was significantly reduced in liraglutide-treated patients compared to untreated patients. The main side effect of liraglutide was mild nausea, except in one patient who experienced severe nausea/vomiting.
Review
Pharmacology & Pharmacy
Baocheng Xie, Shichun Chen, Yongxiang Xu, Weichao Han, Runkai Hu, Minyi Chen, Yusheng Zhang, Shaobo Ding
Summary: Diabetes mellitus and osteoporosis are closely related, and GLP-1RAs may help in controlling blood sugar levels and promoting bone formation, but more research is needed to clarify their specific effects and mechanisms.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Chemistry, Medicinal
O. Kenny, N. P. Brunton, D. Walsh, C. M. Hewage, P. McLoughlin, T. J. Smyth
PHYTOTHERAPY RESEARCH
(2015)
Article
Endocrinology & Metabolism
L. M. McShane, N. Irwin, D. O'Flynn, Z. J. Franklin, C. M. Hewage, F. P. M. O'Harte
JOURNAL OF ENDOCRINOLOGY
(2016)
Article
Chemistry, Physical
Predrag Kukic, Fergal O'Meara, Chandralal Hewage, Jens Erik Nielsen
CHEMICAL PHYSICS LETTERS
(2013)
Review
Chemistry, Medicinal
Chandralal M. Hewage, Kalyana C. Venneti
Article
Chemistry, Inorganic & Nuclear
Aljoscha A. C. Wild, Kevin Fennell, Grace G. Morgan, Chandralal M. Hewage, J. Paul G. Malthouse
DALTON TRANSACTIONS
(2014)
Article
Chemistry, Applied
O. Kenny, T. J. Smyth, C. M. Hewage, N. P. Brunton
Article
Chemistry, Applied
O. Kenny, T. J. Smyth, D. Walsh, C. T. Kelleher, C. M. Hewage, N. P. Brunton
Article
Food Science & Technology
Owen Kenny, Thomas J. Smyth, Chandralal M. Hewage, Nigel P. Brunton
INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY
(2015)
Article
Biochemistry & Molecular Biology
Mohamed A. Elsawy, Chandralal Hewage, Brian Walker
JOURNAL OF PEPTIDE SCIENCE
(2012)
Article
Biochemistry & Molecular Biology
O. Kenny, T. J. Smyth, C. M. Hewage, N. P. Brunton, P. McLoughlin
Article
Biophysics
Silvia Benetti, Patrick Brendan Timmons, Chandralal M. Hewage
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS
(2019)
Article
Biophysics
Patrick Brendan Timmons, Donal O'Flynn, J. Michael Conlon, Chandralal M. Hewage
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS
(2019)
Article
Biochemistry & Molecular Biology
Patrick Brendan Timmons, Donal O'Flynn, J. Michael Conlon, Chandralal M. Hewage
JOURNAL OF PEPTIDE SCIENCE
(2019)
Article
Biochemistry & Molecular Biology
Patrick B. Timmons, Chandralal M. Hewage
Summary: Maximin 1 is a cationic, amphipathic antimicrobial peptide found in the skin secretions and brains of the Chinese red belly toad. This 27 amino acid residue-long peptide adopts an alpha-helical structure and displays flexibility and low hemolytic activity in interaction with a bacterial membrane-mimicking environment.
JOURNAL OF PEPTIDE SCIENCE
(2022)
Article
Multidisciplinary Sciences
Patrick B. Timmons, Chandralal M. Hewage
Summary: Palustrin-Ca is a host defence peptide with potent antimicrobial and anticancer activities, characterized by an alpha-helix and a cyclic disulfide-bridged domain in its structure. Molecular dynamics simulation showed that the peptide interacts with sodium dodecyl sulfate micelles with energetically-favorable hydrophobic and electrostatic contacts.
SCIENTIFIC REPORTS
(2021)
